bluebird bio Provides Updated Findings of AML in LentiGlobin for SCD Gene Therapy Program

Updated Findings from bluebird bio

  • bluebird bio analyses demonstrate lentiviral vector BB305 unlikely to be the cause of AML in a clinical study of LentiGlobin for SCD
  • bluebird bio initiated a process with regulators to resume clinical studies

bluebird bio (BLUE)

This content is for paid subscribers.
Please click here to subscribe or here to log in.